12 May 2022 - - US-based biopharmaceutical company Spectrum Pharmaceuticals (NASDAQ: SPPI) has appointed Nora Brennan as chief financial officer effective May 25, 2022, the company said.

Brennan has served on Spectrum's board of directors and as chairperson of the audit committee since December 2020, and will relinquish her board duties to assume this new role.

Most recently, Brennan served as chief financial officer of Fore Biotherapeutics, a private precision oncology company pioneering the development of cancer therapies driven by functional genomics.

Prior to Fore, she was the chief financial officer of Tela Bio, Inc., where she guided the company through a successful IPO and follow-on financing.

Previously, Brennan spent 11 years as the senior vice president of Treasury and Investor Relations at Integra LifeSciences Holdings Corp., where she served in numerous capacities and led Integra through a myriad of financings.

She was key to the capital markets strategy over a significant period of time and successfully integrated 18 acquisitions leading to significant revenue growth for the company.

She earned her B.A. in Economics from the University of Illinois at Urbana-Champaign and received her MBA from the University of Chicago Booth School of Business.

With Brennan's announcement, Brittany Bradrick, who was recently appointed to the board, will now assume the role of chairperson of the audit committee.

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies.

Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace.

Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need.

This pipeline has the potential to transform the company in the near future.